Abeona Therapeutics Inc. (NASDAQ:ABEO) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Abeona Therapeutics Inc. (NASDAQ:ABEO) have earned an average rating of “Moderate Buy” from the five analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $20.00.

A number of brokerages have recently commented on ABEO. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Abeona Therapeutics in a research report on Monday, October 13th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Abeona Therapeutics in a report on Wednesday. Finally, Wall Street Zen lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th.

Abeona Therapeutics Stock Down 3.7%

Abeona Therapeutics stock opened at $5.16 on Friday. The company has a quick ratio of 9.53, a current ratio of 9.74 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $279.62 million, a P/E ratio of 4.20 and a beta of 1.12. The firm has a 50 day moving average price of $5.08 and a 200-day moving average price of $5.63. Abeona Therapeutics has a twelve month low of $3.93 and a twelve month high of $7.54.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Wednesday, November 12th. The biopharmaceutical company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.17. As a group, equities analysts predict that Abeona Therapeutics will post -1.16 EPS for the current year.

Insider Buying and Selling at Abeona Therapeutics

In related news, SVP Brendan M. O’malley sold 13,578 shares of Abeona Therapeutics stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $5.33, for a total value of $72,370.74. Following the completion of the transaction, the senior vice president directly owned 451,134 shares in the company, valued at approximately $2,404,544.22. The trade was a 2.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark Alvino sold 15,000 shares of the stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $4.74, for a total value of $71,100.00. Following the sale, the director owned 62,252 shares in the company, valued at approximately $295,074.48. This represents a 19.42% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 155,576 shares of company stock valued at $818,520 in the last quarter. Corporate insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ABEO. Aberdeen Group plc purchased a new stake in shares of Abeona Therapeutics in the fourth quarter worth about $3,248,000. SG Americas Securities LLC bought a new stake in Abeona Therapeutics during the 4th quarter worth approximately $57,000. Sherbrooke Park Advisers LLC purchased a new stake in Abeona Therapeutics in the 3rd quarter worth approximately $64,000. Qube Research & Technologies Ltd lifted its stake in Abeona Therapeutics by 568.4% in the 3rd quarter. Qube Research & Technologies Ltd now owns 225,868 shares of the biopharmaceutical company’s stock worth $1,193,000 after purchasing an additional 192,075 shares in the last quarter. Finally, Millennium Management LLC boosted its holdings in Abeona Therapeutics by 176.0% in the 3rd quarter. Millennium Management LLC now owns 709,349 shares of the biopharmaceutical company’s stock valued at $3,745,000 after purchasing an additional 452,334 shares during the period. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.

The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.